|Time Commitment:||2 Hrs 45 min over 90 days|
|Credits Available:||These activities have been approved for AMA PRA Category 1 Credit(s)™, and certified for ANCC Contact Hours (including pharmacotherapeutic contact hours) and California Board of Nursing Contact Hours (Time to complete: Self Study 1.75 hrs; Live Group Discussion 1: 0.5 hrs; Live Group Discussion 2: 0.5 hrs)|
The goal of this experience is to improve adherence to prophylaxis and management of inhibitors in persons with hemophilia A (PwHA). Members of the hemophilia care team who care for PwHA are challenged by the complexity and rarity of the disease as well as its inherently high treatment burden. To successfully overcome these challenges, clinicians who treat hemophilia must be apprised of the latest data on approved and emerging treatments to facilitate patient and caregiver education, improve adherence, and implement personalized treatment plans that balance treatment efficacy and safety. This educational activity is supported by an educational grant from Genentech.
This self-assessment will assess your understanding of hemophilia A. It assesses your knowledge about creating personalized prophylaxis regimens, strategies to improve adherence, managing inhibitors, and recognizing risk factors for inhibitor development.
This module reviews hemophilia A classifications and available therapies. It also reviews clinical data surrounding products used for this disease as well as investigational agents.
This module reviews risk factors for developing inhibitors, testing and monitoring strategies, immune tolerance induction, and the role of bypassing agents. It also discussed trial data and a surveillance program for patients with bleeding disorders.
This module is focused on adherence, barriers to adherence, strategies to improve adherence, and the role of the care team in promoting adherence. The care transition from adolescence to young adulthood and how this impacts adherence is also included.
This self-assessment will assess your knowledge about creating personalized prophylaxis regimens, strategies to improve adherence, managing inhibitors, and recognizing risk factors for inhibitor development at the conclusion of this educational experience.
The first web conference will focus on discussion about personalizing prophylaxis regimens, managing inhibitors, and addressing adherence in patients with hemophilia A.
The second web conference will focus on reviewing the patient case and group tasks and how the findings can apply to caring for current or future patients with hemophilia A.
This group task will focus on addressing adherence and the transition from adolescence to young adulthood in a teenage patient with hemophilia A.
This group task will focus on managing inhibitors in a pediatric patient with severe hemophilia A.
Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.